Splicing: is there an alternative contribution to Parkinson’s disease?

1.

Ward AJ, Cooper TA (2010) The pathobiology of splicing. J Pathol 220(2):152–163. doi:10.1002/path.2649 PubMedCentralPubMed

2.

Yap K, Makeyev EV (2013) Regulation of gene expression in mammalian nervous system through alternative pre-mRNA splicing coupled with RNA quality control mechanisms. Mol Cell Neurosci 56:420–428. doi:10.1016/j.mcn.2013.01.003 PubMedCrossRef

3.

Calarco JA, Zhen M, Blencowe BJ (2011) Networking in a global world: establishing functional connections between neural splicing regulators and their target transcripts. RNA 17(5):775–791. doi:10.1261/rna.2603911 PubMedCentralPubMedCrossRef

4.

Li Q, Lee JA, Black DL (2007) Neuronal regulation of alternative pre-mRNA splicing. Nat Rev Neurosci 8(11):819–831. doi:10.1038/nrn2237 PubMedCrossRef

5.

Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ (2008) Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 40(12):1413–1415. doi:10.1038/ng.259 PubMedCrossRef

6.

Behzadnia N, Golas MM, Hartmuth K, Sander B, Kastner B, Deckert J, Dube P, Will CL, Urlaub H, Stark H, Luhrmann R (2007) Composition and three-dimensional EM structure of double affinity-purified, human prespliceosomal A complexes. EMBO J 26(6):1737–1748. doi:10.1038/sj.emboj.7601631 PubMedCentralPubMedCrossRef

7.

Shefer K, Sperling J, Sperling R (2014) The supraspliceosome—a multi-task machine for regulated pre-mRNA processing in the cell nucleus. Comput Struct Biotechnol J 11(19):113–122. doi:10.1016/j.csbj.2014.09.008 PubMedCentralPubMedCrossRef

8.

Gamazon ER, Stranger BE (2014) Genomics of alternative splicing: evolution, development and pathophysiology. Hum Genet 133(6):679–687. doi:10.1007/s00439-013-1411-3 PubMedCrossRef

9.

Scuderi S, La Cognata V, Drago F, Cavallaro S, D’Agata V (2014) Alternative splicing generates different parkin protein isoforms: evidences in human, rat, and mouse brain. Biomed Res Int 2014:690796. doi:10.1155/2014/690796 PubMedCentralPubMedCrossRef

10.

Licatalosi DD, Darnell RB (2006) Splicing regulation in neurologic disease. Neuron 52(1):93–101. doi:10.1016/j.neuron.2006.09.017 PubMedCrossRef

11.

Tazi J, Bakkour N, Stamm S (2009) Alternative splicing and disease. Biochim Biophys Acta 1792(1):14–26. doi:10.1016/j.bbadis.2008.09.017 PubMedCrossRef

12.

Singh RK, Cooper TA (2012) Pre-mRNA splicing in disease and therapeutics. Trends Mol Med 18(8):472–482. doi:10.1016/j.molmed.2012.06.006 PubMedCentralPubMedCrossRef

13.

Cooper TA, Wan L, Dreyfuss G (2009) RNA and disease. Cell 136(4):777–793. doi:10.1016/j.cell.2009.02.011 PubMedCentralPubMedCrossRef

14.

Lewis PA, Cookson MR (2012) Gene expression in the Parkinson’s disease brain. Brain Res Bull 88(4):302–312. doi:10.1016/j.brainresbull.2011.11.016 PubMedCentralPubMedCrossRef

15.

Bonifati V (2014) Genetics of Parkinson’s disease—state of the art, 2013. Parkinsonism Relat Disord 20(1):S23–S28. doi:10.1016/S1353-8020(13)70009-9 PubMedCrossRef

16.

Lubbe S, Morris HR (2014) Recent advances in Parkinson’s disease genetics. J Neurol 261(2):259–266. doi:10.1007/s00415-013-7003-2 PubMedCrossRef

17.

Trinh J, Farrer M (2013) Advances in the genetics of Parkinson disease. Nat Rev Neurol 9(8):445–454. doi:10.1038/nrneurol.2013.132 PubMedCrossRef

18.

Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, Schulte C, Keller MF, Arepalli S, Letson C, Edsall C, Stefansson H, Liu X, Pliner H, Lee JH, Cheng R, International Parkinson’s Disease Genomics C, Parkinson’s Study Group Parkinson’s Research: The Organized GI, andMe, GenePd, NeuroGenetics Research C, Hussman Institute of Human G, Ashkenazi Jewish Dataset I, Cohorts for H, Aging Research in Genetic E, North American Brain Expression C, United Kingdom Brain Expression C, Greek Parkinson’s Disease C, Alzheimer Genetic Analysis G, Ikram MA, Ioannidis JP, Hadjigeorgiou GM, Bis JC, Martinez M, Perlmutter JS, Goate A, Marder K, Fiske B, Sutherland M, Xiromerisiou G, Myers RH, Clark LN, Stefansson K, Hardy JA, Heutink P, Chen H, Wood NW, Houlden H, Payami H, Brice A, Scott WK, Gasser T, Bertram L, Eriksson N, Foroud T, Singleton AB (2014) Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat Genet 46(9):989–993. doi:10.1038/ng.3043 PubMedCentralPubMedCrossRef

19.

Stefanis L (2012) Alpha-synuclein in Parkinson’s disease. Cold Spring Harb Perspect Med 2(2):a009399. doi:10.1101/cshperspect.a009399 PubMedCentralPubMedCrossRef

20.

Pihlstrom L, Toft M (2011) Genetic variability in SNCA and Parkinson’s disease. Neurogenetics 12(4):283–293. doi:10.1007/s10048-011-0292-7 PubMedCrossRef

21.

Deng H, Yuan L (2014) Genetic variants and animal models in SNCA and Parkinson disease. Ageing Res Rev 15C:161–176. doi:10.1016/j.arr.2014.04.002 CrossRef

22.

Nuytemans K, Meeus B, Crosiers D, Brouwers N, Goossens D, Engelborghs S, Pals P, Pickut B, Van den Broeck M, Corsmit E, Cras P, De Deyn PP, Del-Favero J, Van Broeckhoven C, Theuns J (2009) Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population. Hum Mutat 30(7):1054–1061. doi:10.1002/humu.21007 PubMedCrossRef

23.

Beyer K, Domingo-Sabat M, Lao JI, Carrato C, Ferrer I, Ariza A (2008) Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases. Neurogenetics 9(1):15–23. doi:10.1007/s10048-007-0106-0 PubMedCrossRef

24.

Beyer K, Domingo-Sabat M, Humbert J, Carrato C, Ferrer I, Ariza A (2008) Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease. Neurogenetics 9(3):163–172. doi:10.1007/s10048-008-0124-6 PubMedCrossRef

25.

McLean JR, Hallett PJ, Cooper O, Stanley M, Isacson O (2012) Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson’s disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression. Mol Cell Neurosci 49(2):230–239. doi:10.1016/j.mcn.2011.11.006 PubMedCentralPubMedCrossRef

26.

Cardo LF, Coto E, de Mena L, Ribacoba R, Mata IF, Menendez M, Moris G, Alvarez V (2014) Alpha-synuclein transcript isoforms in three different brain regions from Parkinson’s disease and healthy subjects in relation to the SNCA rs356165/rs11931074 polymorphisms. Neurosci Lett 562:45–49. doi:10.1016/j.neulet.2014.01.009 PubMedCrossRef

27.

Beyer K, Lao JI, Carrato C, Mate JL, Lopez D, Ferrer I, Ariza A (2004) Differential expression of alpha-synuclein isoforms in dementia with Lewy bodies. Neuropathol Appl Neurobiol 30(6):601–607. doi:10.1111/j.1365-2990.2004.00572.x PubMedCrossRef

28.

Beyer K, Humbert J, Ferrer A, Lao JI, Carrato C, Lopez D, Ferrer I, Ariza A (2006) Low alpha-synuclein 126 mRNA levels in dementia with Lewy bodies and Alzheimer disease. Neuroreport 17(12):1327–1330. doi:10.1097/01.wnr.0000224773.66904.e7 PubMedCrossRef

29.

McCarthy JJ, Linnertz C, Saucier L, Burke JR, Hulette CM, Welsh-Bohmer KA, Chiba-Falek O (2011) The effect of SNCA 3′ region on the levels of SNCA-112 splicing variant. Neurogenetics 12(1):59–64. doi:10.1007/s10048-010-0263-4 PubMedCentralPubMedCrossRef

30.

Kalivendi SV, Yedlapudi D, Hillard CJ, Kalyanaraman B (2010) Oxidants induce alternative splicing of alpha-synuclein: implications for Parkinson’s disease. Free Radic Biol Med 48(3):377–383. doi:10.1016/j.freeradbiomed.2009.10.045 PubMedCentralPubMedCrossRef

31.

Rhinn H, Qiang L, Yamashita T, Rhee D, Zolin A, Vanti W, Abeliovich A (2012) Alternative alpha-synuclein transcript usage as a convergent mechanism in Parkinson’s disease pathology. Nat Commun 3:1084. doi:10.1038/ncomms2032 PubMedCentralPubMedCrossRef

32.

Beyer K (2006) Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol 112(3):237–251. doi:10.1007/s00401-006-0104-6 PubMedCrossRef

33.

Bungeroth M, Appenzeller S, Regulin A, Volker W, Lorenzen I, Grotzinger J, Pendziwiat M, Kuhlenbaumer G (2014) Differential aggregation properties of alpha-synuclein isoforms. Neurobiol Aging 35(8):1913–1919. doi:10.1016/j.neurobiolaging.2014.02.009 PubMedCrossRef

34.

Burre J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Sudhof TC (2010) Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329(5999):1663–1667. doi:10.1126/science.1195227 PubMedCentralPubMedCrossRef

35.

Rideout HJ, Stefanis L (2014) The neurobiology of LRRK2 and its role in the pathogenesis of Parkinson’s disease. Neurochem Res 39(3):576–592. doi:10.1007/s11064-013-1073-5 PubMedCrossRef

36.

Johnson J, Paisan-Ruiz C, Lopez G, Crews C, Britton A, Malkani R, Evans EW, McInerney-Leo A, Jain S, Nussbaum RL, Foote KD, Mandel RJ, Crawley A, Reimsnider S, Fernandez HH, Okun MS, Gwinn-Hardy K, Singleton AB (2007) Comprehensive screening of a North American Parkinson’s disease cohort for LRRK2 mutation. Neurodegener Dis 4(5):386–391. doi:10.1159/000105160 PubMedCrossRef

37.

Skipper L, Shen H, Chua E, Bonnard C, Kolatkar P, Tan LC, Jamora RD, Puvan K, Puong KY, Zhao Y, Pavanni R, Wong MC, Yuen Y, Farrer M, Liu JJ, Tan EK (2005) Analysis of LRRK2 functional domains in nondominant Parkinson disease. Neurology 65(8):1319–1321. doi:10.1212/01.wnl.0000180517.70572.37 PubMedCrossRef

38.

Zabetian CP, Samii A, Mosley AD, Roberts JW, Leis BC, Yearout D, Raskind WH, Griffith A (2005) A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology 65(5):741–744. doi:10.1212/01.wnl.0000172630.22804.73 PubMedCrossRef

39.

Shojaee S, Sina F, Farboodi N, Fazlali Z, Ghazavi F, Ghorashi SA, Parsa K, Sadeghi H, Shahidi GA, Ronaghi M, Elahi E (2009) A clinic-based screening of mutations in exons 31, 34, 35, 41, and 48 of LRRK2 in Iranian Parkinson’s disease patients. Mov Disord 24(7):1023–1027. doi:10.1002/mds.22503 PubMedCrossRef

40.

Di Fonzo A, Tassorelli C, De Mari M, Chien HF, Ferreira J, Rohe CF, Riboldazzi G, Antonini A, Albani G, Mauro A, Marconi R, Abbruzzese G, Lopiano L, Fincati E, Guidi M, Marini P, Stocchi F, Onofrj M, Toni V, Tinazzi M, Fabbrini G, Lamberti P, Vanacore N, Meco G, Leitner P, Uitti RJ, Wszolek ZK, Gasser T, Simons EJ, Breedveld GJ, Goldwurm S, Pezzoli G, Sampaio C, Barbosa E, Martignoni E, Oostra BA, Bonifati V, Italian Parkinson’s Genetics N (2006) Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson’s disease. Eur J Hum Genet 14(3):322–331. doi:10.1038/sj.ejhg.5201539 PubMedCrossRef

41.

Grimes DA, Racacho L, Han F, Panisset M, Bulman DE (2007) LRRK2 screening in a Canadian Parkinson’s disease cohort. Can J Neurol Sci 34(3):336–338PubMedCrossRef

42.

Paisan-Ruiz C, Nath P, Washecka N, Gibbs JR, Singleton AB (2008) Comprehensive analysis of LRRK2 in publicly available Parkinson’s disease cases and neurologically normal controls. Hum Mutat 29(4):485–490. doi:10.1002/humu.20668 PubMedCrossRef

43.

Lesage S, Condroyer C, Lannuzel A, Lohmann E, Troiano A, Tison F, Damier P, Thobois S, Ouvrard-Hernandez AM, Rivaud-Pechoux S, Brefel-Courbon C, Destee A, Tranchant C, Romana M, Leclere L, Durr A, Brice A, French Parkinson’s Disease Genetics Study G (2009) Molecular analyses of the LRRK2 gene in European and North African autosomal dominant Parkinson’s disease. J Med Genet 46(7):458–464. doi:10.1136/jmg.2008.062612 PubMedCrossRef

44.

Trabzuni D, Ryten M, Emmett W, Ramasamy A, Lackner KJ, Zeller T, Walker R, Smith C, Lewis PA, Mamais A, de Silva R, Vandrovcova J, International Parkinson Disease Genomics C, Hernandez D, Nalls MA, Sharma M, Garnier S, Lesage S, Simon-Sanchez J, Gasser T, Heutink P, Brice A, Singleton A, Cai H, Schadt E, Wood NW, Bandopadhyay R, Weale ME, Hardy J, Plagnol V (2013) Fine-mapping, gene expression and splicing analysis of the disease associated LRRK2 locus. PLoS ONE 8(8):e70724. doi:10.1371/journal.pone.0070724 PubMedCentralPubMedCrossRef

45.

Giesert F, Hofmann A, Burger A, Zerle J, Kloos K, Hafen U, Ernst L, Zhang J, Vogt-Weisenhorn DM, Wurst W (2013) Expression analysis of Lrrk1, Lrrk2 and Lrrk2 splice variants in mice. PLoS ONE 8(5):e63778. doi:10.1371/journal.pone.0063778 PubMedCentralPubMedCrossRef

46.

Sheng D, Qu D, Kwok KH, Ng SS, Lim AY, Aw SS, Lee CW, Sung WK, Tan EK, Lufkin T, Jesuthasan S, Sinnakaruppan M, Liu J (2010) Deletion of the WD40 domain of LRRK2 in zebrafish causes parkinsonism-like loss of neurons and locomotive defect. PLoS Genet 6(4):e1000914. doi:10.1371/journal.pgen.1000914 PubMedCentralPubMedCrossRef

47.

Vilarino-Guell C, Wider C, Ross OA, Dachsel JC, Kachergus JM, Lincoln SJ, Soto-Ortolaza AI, Cobb SA, Wilhoite GJ, Bacon JA, Behrouz B, Melrose HL, Hentati E, Puschmann A, Evans DM, Conibear E, Wasserman WW, Aasly JO, Burkhard PR, Djaldetti R, Ghika J, Hentati F, Krygowska-Wajs A, Lynch T, Melamed E, Rajput A, Rajput AH, Solida A, Wu RM, Uitti RJ, Wszolek ZK, Vingerhoets F, Farrer MJ (2011) VPS35 mutations in Parkinson disease. Am J Hum Genet 89(1):162–167. doi:10.1016/j.ajhg.2011.06.001 PubMedCentralPubMedCrossRef

48.

Zimprich A, Benet-Pages A, Struhal W, Graf E, Eck SH, Offman MN, Haubenberger D, Spielberger S, Schulte EC, Lichtner P, Rossle SC, Klopp N, Wolf E, Seppi K, Pirker W, Presslauer S, Mollenhauer B, Katzenschlager R, Foki T, Hotzy C, Reinthaler E, Harutyunyan A, Kralovics R, Peters A, Zimprich F, Brucke T, Poewe W, Auff E, Trenkwalder C, Rost B, Ransmayr G, Winkelmann J, Meitinger T, Strom TM (2011) A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet 89(1):168–175. doi:10.1016/j.ajhg.2011.06.008 PubMedCentralPubMedCrossRef

49.

Verstraeten A, Wauters E, Crosiers D, Meeus B, Corsmit E, Elinck E, Mattheijssens M, Peeters K, Cras P, Pickut B, Vandenberghe R, Engelborghs S, De Deyn PP, Van Broeckhoven C (1844) Theuns J (2012) Contribution of VPS35 genetic variability to LBD in the Flanders–Belgian population. Neurobiol Aging 33(8):e1811–e1843. doi:10.1016/j.neurobiolaging.2012.01.006

50.

Bonifati V (2012) Autosomal recessive parkinsonism. Parkinsonism Relat Disord 18(1):S4–S6. doi:10.1016/S1353-8020(11)70004-9 PubMedCrossRef

51.

Lucking CB, Durr A, Bonifati V, Vaughan J, De Michele G, Gasser T, Harhangi BS, Meco G, Denefle P, Wood NW, Agid Y, Brice A, French Parkinson’s Disease Genetics Study G, European Consortium on Genetic Susceptibility in Parkinson’s D (2000) Association between early-onset Parkinson’s disease and mutations in the parkin gene. N Engl J Med 342(21):1560–1567. doi:10.1056/NEJM200005253422103 PubMedCrossRef

52.

Oliveira SA, Scott WK, Martin ER, Nance MA, Watts RL, Hubble JP, Koller WC, Pahwa R, Stern MB, Hiner BC, Ondo WG, Allen FH Jr, Scott BL, Goetz CG, Small GW, Mastaglia F, Stajich JM, Zhang F, Booze MW, Winn MP, Middleton LT, Haines JL, Pericak-Vance MA, Vance JM (2003) Parkin mutations and susceptibility alleles in late-onset Parkinson’s disease. Ann Neurol 53(5):624–629. doi:10.1002/ana.10524 PubMedCrossRef

53.

Illarioshkin SN, Periquet M, Rawal N, Lucking CB, Zagorovskaya TB, Slominsky PA, Miloserdova OV, Markova ED, Limborska SA, Ivanova-Smolenskaya IA, Brice A (2003) Mutation analysis of the parkin gene in Russian families with autosomal recessive juvenile parkinsonism. Mov Disord 18(8):914–919. doi:10.1002/mds.10467 PubMedCrossRef

54.

Pigullo S, De Luca A, Barone P, Marchese R, Bellone E, Colosimo A, Scaglione C, Martinelli P, Di Maria E, Pizzuti A, Abbruzzese G, Dallapiccola B, Ajmar F, Mandich P (2004) Mutational analysis of parkin gene by denaturing high-performance liquid chromatography (DHPLC) in essential tremor. Parkinsonism Relat Disord 10(6):357–362. doi:10.1016/j.parkreldis.2004.04.012 PubMedCrossRef

55.

Scherfler C, Khan NL, Pavese N, Eunson L, Graham E, Lees AJ, Quinn NP, Wood NW, Brooks DJ, Piccini PP (2004) Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain 127(Pt 6):1332–1342. doi:10.1093/brain/awh150 PubMedCrossRef

56.

Bertoli-Avella AM, Giroud-Benitez JL, Akyol A, Barbosa E, Schaap O, van der Linde HC, Martignoni E, Lopiano L, Lamberti P, Fincati E, Antonini A, Stocchi F, Montagna P, Squitieri F, Marini P, Abbruzzese G, Fabbrini G, Marconi R, Dalla Libera A, Trianni G, Guidi M, De Gaetano A, Boff Maegawa G, De Leo A, Gallai V, de Rosa G, Vanacore N, Meco G, van Duijn CM, Oostra BA, Heutink P, Bonifati V, Italian Parkinson Genetics N (2005) Novel parkin mutations detected in patients with early-onset Parkinson’s disease. Mov Disord 20(4):424–431. doi:10.1002/mds.20343 PubMedCrossRef

57.

Bardien S, Keyser R, Yako Y, Lombard D, Carr J (2009) Molecular analysis of the parkin gene in South African patients diagnosed with Parkinson’s disease. Parkinsonism Relat Disord 15(2):116–121. doi:10.1016/j.parkreldis.2008.04.005 PubMedCrossRef

58.

Pankratz N, Kissell DK, Pauciulo MW, Halter CA, Rudolph A, Pfeiffer RF, Marder KS, Foroud T, Nichols WC, Parkinson Study Group PI (2009) Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations. Neurology 73(4):279–286. doi:10.1212/WNL.0b013e3181af7a33 PubMedCentralPubMedCrossRef

59.

La Cognata V, Iemmolo R, D’Agata V, Scuderi S, Drago F, Zappia M, Cavallaro S (2014) Increasing the coding potential of genomes through alternative splicing: the case of PARK2 gene. Curr Genomics 15(3):203–216. doi:10.2174/1389202915666140426003342 PubMedCentralPubMedCrossRef

60.

Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392(6676):605–608PubMedCrossRef

61.

Matsumine H, Saito M, Shimoda-Matsubayashi S, Tanaka H, Ishikawa A, Nakagawa-Hattori Y, Yokochi M, Kobayashi T, Igarashi S, Takano H, Sanpei K, Koike R, Mori H, Kondo T, Mizutani Y, Schaffer AA, Yamamura Y, Nakamura S, Kuzuhara S, Tsuji S, Mizuno Y (1997) Localization of a gene for an autosomal recessive form of juvenile parkinsonism to chromosome 6q25.2–27. Am J Hum Genet 60(3):588–596PubMedCentralPubMed

62.

Xu L, Lin DC, Yin D, Koeffler HP (2014) An emerging role of PARK2 in cancer. J Mol Med (Berl) 92(1):31–42. doi:10.1007/s00109-013-1107-0 CrossRef

63.

Ikeuchi K, Marusawa H, Fujiwara M, Matsumoto Y, Endo Y, Watanabe T, Iwai A, Sakai Y, Takahashi R, Chiba T (2009) Attenuation of proteolysis-mediated cyclin E regulation by alternatively spliced parkin in human colorectal cancers. Int J Cancer 125(9):2029–2035. doi:10.1002/ijc.24565 PubMedCrossRef

64.

Kitada T, Asakawa S, Minoshima S, Mizuno Y, Shimizu N (2000) Molecular cloning, gene expression, and identification of a splicing variant of the mouse parkin gene. Mamm Genome 11(6):417–421PubMedCrossRef

65.

Humbert J, Beyer K, Carrato C, Mate JL, Ferrer I, Ariza A (2007) Parkin and synphilin-1 isoform expression changes in Lewy body diseases. Neurobiol Dis 26(3):681–687. doi:10.1016/j.nbd.2007.03.007 PubMedCrossRef

66.

Tan EK, Shen H, Tan JM, Lim KL, Fook-Chong S, Hu WP, Paterson MC, Chandran VR, Yew K, Tan C, Yuen Y, Pavanni R, Wong MC, Puvan K, Zhao Y (2005) Differential expression of splice variant and wild-type parkin in sporadic Parkinson’s disease. Neurogenetics 6(4):179–184. doi:10.1007/s10048-005-0001-5 PubMedCrossRef

67.

Dagata V, Cavallaro S (2004) Parkin transcript variants in rat and human brain. Neurochem Res 29(9):1715–1724PubMedCrossRef

68.

Sunada Y, Saito F, Matsumura K, Shimizu T (1998) Differential expression of the parkin gene in the human brain and peripheral leukocytes. Neurosci Lett 254(3):180–182PubMedCrossRef

69.

Solano SM, Miller DW, Augood SJ, Young AB, Penney JB Jr (2000) Expression of alpha-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson’s disease. Ann Neurol 47(2):201–210PubMedCrossRef

70.

Kasap M, Akpinar G, Sazci A, Idrisoglu HA, Vahaboglu H (2009) Evidence for the presence of full-length PARK2 mRNA and parkin protein in human blood. Neurosci Lett 460(3):196–200. doi:10.1016/j.neulet.2009.05.079 PubMedCrossRef

71.

Pawlyk AC, Giasson BI, Sampathu DM, Perez FA, Lim KL, Dawson VL, Dawson TM, Palmiter RD, Trojanowski JQ, Lee VM (2003) Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age. J Biol Chem 278(48):48120–48128. doi:10.1074/jbc.M306889200 PubMedCrossRef

72.

Horowitz JM, Myers J, Stachowiak MK, Torres G (1999) Identification and distribution of Parkin in rat brain. Neuroreport 10(16):3393–3397PubMedCrossRef

73.

Stichel CC, Augustin M, Kuhn K, Zhu XR, Engels P, Ullmer C, Lubbert H (2000) Parkin expression in the adult mouse brain. Eur J Neurosci 12(12):4181–4194PubMed

74.

Gu WJ, Abbas N, Lagunes MZ, Parent A, Pradier L, Bohme GA, Agid Y, Hirsch EC, Raisman-Vozari R, Brice A (2000) Cloning of rat parkin cDNA and distribution of parkin in rat brain. J Neurochem 74(4):1773–1776PubMedCrossRef

75.

Huynh DP, Dy M, Nguyen D, Kiehl TR, Pulst SM (2001) Differential expression and tissue distribution of parkin isoforms during mouse development. Brain Res Dev Brain Res 130(2):173–181PubMedCrossRef

76.

D’Agata V, Grimaldi M, Pascale A, Cavallaro S (2000) Regional and cellular expression of the parkin gene in the rat cerebral cortex. Eur J Neurosci 12(10):3583–3588PubMedCrossRef

77.

Pogson JH, Ivatt RM, Whitworth AJ (2011) Molecular mechanisms of PINK1-related neurodegeneration. Curr Neurol Neurosci Rep 11(3):283–290. doi:10.1007/s11910-011-0187-x PubMedCrossRef

78.

Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C (2010) Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat 31(7):763–780. doi:10.1002/humu.21277 PubMedCentralPubMedCrossRef

79.

Marongiu R, Brancati F, Antonini A, Ialongo T, Ceccarini C, Scarciolla O, Capalbo A, Benti R, Pezzoli G, Dallapiccola B, Goldwurm S, Valente EM (2007) Whole gene deletion and splicing mutations expand the PINK1 genotypic spectrum. Hum Mutat 28(1):98. doi:10.1002/humu.9472 PubMedCrossRef

80.

Samaranch L, Lorenzo-Betancor O, Arbelo JM, Ferrer I, Lorenzo E, Irigoyen J, Pastor MA, Marrero C, Isla C, Herrera-Henriquez J, Pastor P (2010) PINK1-linked parkinsonism is associated with Lewy body pathology. Brain 133(Pt 4):1128–1142. doi:10.1093/brain/awq051 PubMedCrossRef

81.

Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, Gonzalez-Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW (2004) Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science 304(5674):1158–1160. doi:10.1126/science.1096284 PubMedCrossRef

82.

Silvestri L, Caputo V, Bellacchio E, Atorino L, Dallapiccola B, Valente EM, Casari G (2005) Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum Mol Genet 14(22):3477–3492. doi:10.1093/hmg/ddi377 PubMedCrossRef

83.

Beilina A, Van Der Brug M, Ahmad R, Kesavapany S, Miller DW, Petsko GA, Cookson MR (2005) Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc Natl Acad Sci U S A 102(16):5703–5708. doi:10.1073/pnas.0500617102 PubMedCentralPubMedCrossRef

84.

d’Amora M, Angelini C, Marcoli M, Cervetto C, Kitada T, Vallarino M (2011) Expression of PINK1 in the brain, eye and ear of mouse during embryonic development. J Chem Neuroanat 41(2):73–85. doi:10.1016/j.jchemneu.2010.11.004 PubMedCrossRef

85.

Lin W, Kang UJ (2008) Characterization of PINK1 processing, stability, and subcellular localization. J Neurochem 106(1):464–474. doi:10.1111/j.1471-4159.2008.05398.x PubMedCentralPubMedCrossRef

86.

Deas E, Plun-Favreau H, Gandhi S, Desmond H, Kjaer S, Loh SH, Renton AE, Harvey RJ, Whitworth AJ, Martins LM, Abramov AY, Wood NW (2011) PINK1 cleavage at position A103 by the mitochondrial protease PARL. Hum Mol Genet 20(5):867–879. doi:10.1093/hmg/ddq526 PubMedCentralPubMedCrossRef

87.

Lockhart PJ, Lincoln S, Hulihan M, Kachergus J, Wilkes K, Bisceglio G, Mash DC, Farrer MJ (2004) DJ-1 mutations are a rare cause of recessively inherited early onset parkinsonism mediated by loss of protein function. J Med Genet 41(3):e22PubMedCentralPubMedCrossRef

88.

Moore DJ, West AB, Dawson VL, Dawson TM (2005) Molecular pathophysiology of Parkinson’s disease. Annu Rev Neurosci 28:57–87. doi:10.1146/annurev.neuro.28.061604.135718 PubMedCrossRef

89.

Bonifati V, Rizzu P, Squitieri F, Krieger E, Vanacore N, van Swieten JC, Brice A, van Duijn CM, Oostra B, Meco G, Heutink P (2003) DJ-1( PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol Sci 24(3):159–160. doi:10.1007/s10072-003-0108-0 PubMedCrossRef

90.

van Duijn CM, Dekker MC, Bonifati V, Galjaard RJ, Houwing-Duistermaat JJ, Snijders PJ, Testers L, Breedveld GJ, Horstink M, Sandkuijl LA, van Swieten JC, Oostra BA, Heutink P (2001) Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am J Hum Genet 69(3):629–634. doi:10.1086/322996 PubMedCentralPubMedCrossRef

91.

Corti O, Lesage S, Brice A (2011) What genetics tells us about the causes and mechanisms of Parkinson’s disease. Physiol Rev 91(4):1161–1218. doi:10.1152/physrev.00022.2010 PubMedCrossRef

92.

Tarantino P, Civitelli D, Annesi F, De Marco EV, Rocca FE, Pugliese P, Nicoletti G, Carrideo S, Provenzano G, Annesi G, Quattrone A (2009) Compound heterozygosity in DJ-1 gene non-coding portion related to parkinsonism. Parkinsonism Relat Disord 15(4):324–326. doi:10.1016/j.parkreldis.2008.07.001 PubMedCrossRef

93.

Hedrich K, Djarmati A, Schafer N, Hering R, Wellenbrock C, Weiss PH, Hilker R, Vieregge P, Ozelius LJ, Heutink P, Bonifati V, Schwinger E, Lang AE, Noth J, Bressman SB, Pramstaller PP, Riess O, Klein C (2004) DJ-1 (PARK7) mutations are less frequent than parkin (PARK2) mutations in early-onset Parkinson disease. Neurology 62(3):389–394PubMedCrossRef

94.

Lev N, Roncevic D, Ickowicz D, Melamed E, Offen D (2006) Role of DJ-1 in Parkinson’s disease. J Mol Neurosci 29(3):215–225PubMedCrossRef

95.

Ariga H, Takahashi-Niki K, Kato I, Maita H, Niki T, Iguchi-Ariga SM (2013) Neuroprotective function of DJ-1 in Parkinson’s disease. Oxid Med Cell Longev 2013:683920. doi:10.1155/2013/683920 PubMedCentralPubMedCrossRef

96.

Xu J, Zhong N, Wang H, Elias JE, Kim CY, Woldman I, Pifl C, Gygi SP, Geula C, Yankner BA (2005) The Parkinson’s disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis. Hum Mol Genet 14(9):1231–1241. doi:10.1093/hmg/ddi134 PubMedCrossRef

97.

Bandopadhyay R, Kingsbury AE, Cookson MR, Reid AR, Evans IM, Hope AD, Pittman AM, Lashley T, Canet-Aviles R, Miller DW, McLendon C, Strand C, Leonard AJ, Abou-Sleiman PM, Healy DG, Ariga H, Wood NW, de Silva R, Revesz T, Hardy JA, Lees AJ (2004) The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson’s disease. Brain 127(Pt 2):420–430. doi:10.1093/brain/awh054 PubMedCrossRef

98.

Besong Agbo D, Klafki H, Poschmann G, Seyfarth K, Genius J, Janssen C, Stuhler K, Wurst W, Meyer HE, Klingenspor M, Wiltfang J (2013) Development of a capillary isoelectric focusing immunoassay to measure DJ-1 isoforms in biological samples. Anal Biochem 443(2):197–204. doi:10.1016/j.ab.2013.09.013 PubMedCrossRef

99.

Kumaran R, Kingsbury A, Coulter I, Lashley T, Williams D, de Silva R, Mann D, Revesz T, Lees A, Bandopadhyay R (2007) DJ-1 (PARK7) is associated with 3R and 4R tau neuronal and glial inclusions in neurodegenerative disorders. Neurobiol Dis 28(1):122–132. doi:10.1016/j.nbd.2007.07.012 PubMedCrossRef

100.

Kumaran R, Vandrovcova J, Luk C, Sharma S, Renton A, Wood NW, Hardy JA, Lees AJ, Bandopadhyay R (2009) Differential DJ-1 gene expression in Parkinson’s disease. Neurobiol Dis 36(2):393–400. doi:10.1016/j.nbd.2009.08.011 PubMedCrossRef

101.

Lin X, Cook TJ, Zabetian CP, Leverenz JB, Peskind ER, Hu SC, Cain KC, Pan C, Edgar JS, Goodlett DR, Racette BA, Checkoway H, Montine TJ, Shi M, Zhang J (2012) DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease. Sci Rep 2:954. doi:10.1038/srep00954 PubMedCentralPubMed

102.

Zhong N, Kim CY, Rizzu P, Geula C, Porter DR, Pothos EN, Squitieri F, Heutink P, Xu J (2006) DJ-1 transcriptionally up-regulates the human tyrosine hydroxylase by inhibiting the sumoylation of pyrimidine tract-binding protein-associated splicing factor. J Biol Chem 281(30):20940–20948. doi:10.1074/jbc.M601935200 PubMedCrossRef

103.

Vilarino-Guell C, Soto AI, Lincoln SJ, Ben Yahmed S, Kefi M, Heckman MG, Hulihan MM, Chai H, Diehl NN, Amouri R, Rajput A, Mash DC, Dickson DW, Middleton LT, Gibson RA, Hentati F, Farrer MJ (2009) ATP13A2 variability in Parkinson disease. Hum Mutat 30(3):406–410. doi:10.1002/humu.20877 PubMedCentralPubMedCrossRef

104.

Murphy KE, Cottle L, Gysbers AM, Cooper AA, Halliday GM (2013) ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies. Acta Neuropathol Commun 1(1):11. doi:10.1186/2051-5960-1-11 PubMedCentralPubMedCrossRef

105.

Ugolino J, Fang S, Kubisch C, Monteiro MJ (2011) Mutant Atp13a2 proteins involved in parkinsonism are degraded by ER-associated degradation and sensitize cells to ER-stress induced cell death. Hum Mol Genet 20(18):3565–3577. doi:10.1093/hmg/ddr274 PubMedCentralPubMedCrossRef

106.

Lu CS, Lai SC, Wu RM, Weng YH, Huang CL, Chen RS, Chang HC, Wu-Chou YH, Yeh TH (2012) PLA2G6 mutations in PARK14-linked young-onset parkinsonism and sporadic Parkinson’s disease. Am J Med Genet B Neuropsychiatr Genet 159B(2):183–191. doi:10.1002/ajmg.b.32012 PubMedCrossRef

107.

Di Fonzo A, Dekker MC, Montagna P, Baruzzi A, Yonova EH, Correia Guedes L, Szczerbinska A, Zhao T, Dubbel-Hulsman LO, Wouters CH, de Graaff E, Oyen WJ, Simons EJ, Breedveld GJ, Oostra BA, Horstink MW, Bonifati V (2009) FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology 72(3):240–245. doi:10.1212/01.wnl.0000338144.10967.2b PubMedCrossRef

108.

Deng H, Liang H, Jankovic J (2013) F-box only protein 7 gene in parkinsonian-pyramidal disease. JAMA Neurol 70(1):20–24. doi:10.1001/jamaneurol.2013.572 PubMedCrossRef

109.

Gomez-Garre P, Jesus S, Carrillo F, Caceres-Redondo MT, Huertas-Fernandez I, Bernal-Bernal I, Bonilla-Toribio M, Vargas-Gonzalez L, Carballo M, Mir P (2014) Systematic mutational analysis of FBXO7 in a Parkinson’s disease population from southern Spain. Neurobiol Aging 35(3):727. e5–7. doi:10.1016/j.neurobiolaging.2013.09.011

110.

Ilyin GP, Rialland M, Pigeon C, Guguen-Guillouzo C (2000) cDNA cloning and expression analysis of new members of the mammalian F-box protein family. Genomics 67(1):40–47. doi:10.1006/geno.2000.6211 PubMedCrossRef

111.

Zhao T, De Graaff E, Breedveld GJ, Loda A, Severijnen LA, Wouters CH, Verheijen FW, Dekker MC, Montagna P, Willemsen R, Oostra BA, Bonifati V (2011) Loss of nuclear activity of the FBXO7 protein in patients with parkinsonian-pyramidal syndrome (PARK15). PLoS ONE 6(2):e16983. doi:10.1371/journal.pone.0016983 PubMedCentralPubMedCrossRef

112.

Nolte D, Niemann S, Muller U (2003) Specific sequence changes in multiple transcript system DYT3 are associated with X-linked dystonia parkinsonism. Proc Natl Acad Sci U S A 100(18):10347–10352. doi:10.1073/pnas.1831949100 PubMedCentralPubMedCrossRef

113.

Herzfeld T, Nolte D, Grznarova M, Hofmann A, Schultze JL, Muller U (2013) X-linked dystonia parkinsonism syndrome (XDP, lubag): disease-specific sequence change DSC3 in TAF1/DYT3 affects genes in vesicular transport and dopamine metabolism. Hum Mol Genet 22(5):941–951. doi:10.1093/hmg/dds499 PubMedCrossRef

114.

Korvatska O, Strand NS, Berndt JD, Strovas T, Chen DH, Leverenz JB, Kiianitsa K, Mata IF, Karakoc E, Greenup JL, Bonkowski E, Chuang J, Moon RT, Eichler EE, Nickerson DA, Zabetian CP, Kraemer BC, Bird TD, Raskind WH (2013) Altered splicing of ATP6AP2 causes X-linked parkinsonism with spasticity (XPDS). Hum Mol Genet 22(16):3259–3268. doi:10.1093/hmg/ddt180 PubMedCentralPubMedCrossRef

115.

Myhre R, Klungland H, Farrer MJ, Aasly JO (2008) Genetic association study of synphilin-1 in idiopathic Parkinson’s disease. BMC Med Genet 9:19. doi:10.1186/1471-2350-9-19 PubMedCentralPubMedCrossRef

116.

Keyser RJ, Oppon E, Carr JA, Bardien S (2011) Identification of Parkinson’s disease candidate genes using CAESAR and screening of MAPT and SNCAIP in South African Parkinson’s disease patients. J Neural Transm 118(6):889–897. doi:10.1007/s00702-011-0591-z PubMedCrossRef

117.

Marx FP, Holzmann C, Strauss KM, Li L, Eberhardt O, Gerhardt E, Cookson MR, Hernandez D, Farrer MJ, Kachergus J, Engelender S, Ross CA, Berger K, Schols L, Schulz JB, Riess O, Kruger R (2003) Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson’s disease. Hum Mol Genet 12(11):1223–1231PubMedCrossRef

118.

Eyal A, Szargel R, Avraham E, Liani E, Haskin J, Rott R, Engelender S (2006) Synphilin-1A: an aggregation-prone isoform of synphilin-1 that causes neuronal death and is present in aggregates from alpha-synucleinopathy patients. Proc Natl Acad Sci U S A 103(15):5917–5922. doi:10.1073/pnas.0509707103 PubMedCentralPubMedCrossRef

119.

Eyal A, Engelender S (2006) Synphilin isoforms and the search for a cellular model of Lewy body formation in Parkinson’s disease. Cell Cycle 5(18):2082–2086PubMedCrossRef

120.

Szargel R, Rott R, Engelender S (2008) Synphilin-1 isoforms in Parkinson’s disease: regulation by phosphorylation and ubiquitylation. Cell Mol Life Sci 65(1):80–88. doi:10.1007/s00018-007-7343-0 PubMedCrossRef

121.

Lei P, Ayton S, Finkelstein DI, Adlard PA, Masters CL, Bush AI (2010) Tau protein: relevance to Parkinson’s disease. Int J Biochem Cell Biol 42(11):1775–1778. doi:10.1016/j.biocel.2010.07.016 PubMedCrossRef

122.

Spatola M, Wider C (2014) Genetics of Parkinson’s disease: the yield. Parkinsonism Relat Disord 20(1):S35–S38. doi:10.1016/S1353-8020(13)70011-7 PubMedCrossRef

123.

Svobodova E, Mrazova L, Luksan O, Elstein D, Zimran A, Stolnaya L, Minks J, Eberova J, Dvorakova L, Jirsa M, Hrebicek M (2011) Glucocerebrosidase gene has an alternative upstream promoter, which has features and expression characteristic of housekeeping genes. Blood Cells Mol Dis 46(3):239–245. doi:10.1016/j.bcmd.2010.12.011 PubMedCrossRef

124.

Jakubauskiene E, Janaviciute V, Peciuliene I, Soderkvist P, Kanopka A (2012) G/A polymorphism in intronic sequence affects the processing of MAO-B gene in patients with Parkinson disease. FEBS Lett 586(20):3698–3704. doi:10.1016/j.febslet.2012.08.028 PubMedCrossRef

125.

Thomas T (2000) Monoamine oxidase-B inhibitors in the treatment of Alzheimer’s disease. Neurobiol Aging 21(2):343–348PubMedCrossRef

126.

Stern G (1998) Neuroprotection by selegiline and other MAO inhibitors. J Neural Transm Suppl 52:99–107PubMedCrossRef

127.

Ho SL, Kapadi AL, Ramsden DB, Williams AC (1995) An allelic association study of monoamine oxidase B in Parkinson’s disease. Ann Neurol 37(3):403–405. doi:10.1002/ana.410370318 PubMedCrossRef

128.

Kurth JH, Kurth MC, Poduslo SE, Schwankhaus JD (1993) Association of a monoamine oxidase B allele with Parkinson’s disease. Ann Neurol 33(4):368–372. doi:10.1002/ana.410330406 PubMedCrossRef

129.

Sobell JL, Lind TJ, Hebrink DD, Heston LL, Sommer SS (1997) Screening the monoamine oxidase B gene in 100 male patients with schizophrenia: a cluster of polymorphisms in African-Americans but lack of functionally significant sequence changes. Am J Med Genet 74(1):44–49PubMedCrossRef

130.

Shehadeh LA, Yu K, Wang L, Guevara A, Singer C, Vance J, Papapetropoulos S (2010) SRRM2, a potential blood biomarker revealing high alternative splicing in Parkinson’s disease. PLoS ONE 5(2):e9104. doi:10.1371/journal.pone.0009104 PubMedCentralPubMedCrossRef

131.

Stamper C, Siegel A, Liang WS, Pearson JV, Stephan DA, Shill H, Connor D, Caviness JN, Sabbagh M, Beach TG, Adler CH, Dunckley T (2008) Neuronal gene expression correlates of Parkinson’s disease with dementia. Mov Disord 23(11):1588–1595. doi:10.1002/mds.22184 PubMedCentralPubMedCrossRef

132.

Soreq L, Bergman H, Israel Z, Soreq H (2012) Exon arrays reveal alternative splicing aberrations in Parkinson’s disease leukocytes. Neurodegener Dis 10(1–4):203–206. doi:10.1159/000332598 PubMedCrossRef

133.

Soreq L, Bergman H, Israel Z, Soreq H (2013) Deep brain stimulation modulates nonsense-mediated RNA decay in Parkinson’s patients leukocytes. BMC Genomics 14:478. doi:10.1186/1471-2164-14-478 PubMedCentralPubMedCrossRef

134.

Potashkin JA, Santiago JA, Ravina BM, Watts A, Leontovich AA (2012) Biosignatures for Parkinson’s disease and atypical parkinsonian disorders patients. PLoS ONE 7(8):e43595. doi:10.1371/journal.pone.0043595 PubMedCentralPubMedCrossRef

135.

Santiago JA, Scherzer CR, Harvard Biomarker S, Potashkin JA (2013) Specific splice variants are associated with Parkinson’s disease. Mov Disord 28(12):1724–1727. doi:10.1002/mds.25635 PubMedCrossRef

136.

Soreq L, Guffanti A, Salomonis N, Simchovitz A, Israel Z, Bergman H, Soreq H (2014) Long non-coding RNA and alternative splicing modulations in Parkinson’s leukocytes identified by RNA sequencing. PLoS Comput Biol 10(3):e1003517. doi:10.1371/journal.pcbi.1003517 PubMedCentralPubMedCrossRef

137.

Soreq L, Salomonis N, Bronstein M, Greenberg DS, Israel Z, Bergman H, Soreq H (2013) Small RNA sequencing-microarray analyses in Parkinson leukocytes reveal deep brain stimulation-induced splicing changes that classify brain region transcriptomes. Front Mol Neurosci 6:10. doi:10.3389/fnmol.2013.00010 PubMedCentralPubMedCrossRef

At a glance: The STEP trials

Springer Medicine

Splicing: is there an alternative contribution to Parkinson’s disease?

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2015

A de novo t(10;19)(q22.3;q13.33) leads to ZMIZ1/PRR12 reciprocal fusion transcripts in a girl with intellectual disability and neuropsychiatric alterations

Acknowledgement to Referees 2014/2015

Adult-onset glutaric aciduria type I presenting with white matter abnormalities and subependymal nodules

In silico analysis of SIGMAR1 variant (rs4879809) segregating in a consanguineous Pakistani family showing amyotrophic lateral sclerosis without frontotemporal lobar dementia

Deletion of Inpp5a causes ataxia and cerebellar degeneration in mice

Variable expression of microglial DAP12 and TREM2 genes in Nasu-Hakola disease